ARARIS BIOTECH
Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.
ARARIS BIOTECH
Social Links:
Industry:
Biotechnology Health Care
Founded:
2019-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.ararisbiotech.com
Total Employee:
1+
Status:
Active
Contact:
+41 56 310 45 98
Email Addresses:
[email protected]
Total Funding:
43.43 M USD
Technology used in webpage:
Swiss Server Location
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Innosuisse
Innosuisse investment in Grant - Araris Biotech
Samsung Ventures
Samsung Ventures investment in Venture Round - Araris Biotech
VI Partners
VI Partners investment in Series A - Araris Biotech
Pureos Bioventures
Pureos Bioventures investment in Series A - Araris Biotech
4BIO Capital
4BIO Capital investment in Series A - Araris Biotech
b2venture
b2venture investment in Series A - Araris Biotech
Follicular Lymphoma Innovation
Follicular Lymphoma Innovation investment in Series A - Araris Biotech
Wille Finance
Wille Finance investment in Series A - Araris Biotech
redalpine
redalpine investment in Series A - Araris Biotech
Schroders Capital
Schroders Capital investment in Series A - Araris Biotech
Key Employee Changes
| Date | New article |
|---|---|
| 2022-10-12 | Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer |
Official Site Inspections
http://www.ararisbiotech.com Semrush global rank: 4.85 M Semrush visits lastest month: 1.79 K
- Host name: sl1197.web.hostpoint.ch
- IP address: 217.26.61.82
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Araris Biotech"
Araris Biotech
Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker …See details»
Araris Biotech - Crunchbase Company Profile & Funding
Araris Biotech is a biotechnology platform enables the attachment of any payload to ‘off the shelf’ antibodies. View contacts for Araris Biotech to access new leads and connect with decision-makers. Araris Biotech AG (Araris) is a …See details»
ararisbiotech.com Reviews: Is this site a scam or legit?
Araris Biotech Company Profile | Management and Employees List
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology.See details»
Araris Biotech AG – Swiss Biotech
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology.See details»
Araris Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Araris. Use the PitchBook Platform to explore the full profile.See details»
Araris Biotech AG - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Email: [email protected] ICR HealthcareTel: +44 (0) 20 3709 5700Amber Fennell, Kate Coyle, Jon YuEmail: [email protected] The content above comes from …See details»
Araris Biotech AG - life-sciences-europe.com
Jan 31, 2019 BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) EuropaBio aisbl – the European Association of Bioindustries; BioIndustry …See details»
Araris Biotech AG - startup.ch
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology.See details»
Araris Biotech Company Information - Funding, Investors, and More
The company Araris Biotech has raised a total of $26.81m in funding over 3 rounds. Get information on funding, investors, industries, and more for Araris Biotech. See Araris Biotech …See details»
Araris Biotech - Overview, News & Similar companies - ZoomInfo
Feb 7, 2024 Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator Grant from Innosuisse to Develop Antibody-Drug Conjugate Candidates AU ZH, Switzerland, May 05, …See details»
Araris Biotech Closes $24 Million Financing Round
Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich. For more information, please visit www.ararisbiotech.com or follow Araris on Twitter and LinkedIn.See details»
Araris Biotech AG - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Araris Biotech AG of Au, ZÜRICH. Get the latest business insights from Dun & Bradstreet.See details»
Araris Biotech - Craft
Araris Biotech is a company that develops ADC-based safe and potent drugs for various diseases and ailments. Its linker platform enables the attachment of any payload to "off-the-shelf" …See details»
Araris Biotech AG - VentureRadar
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together.See details»
Araris Biotech AG Initiates Leadership Transition to Advance Next ...
For more information, please visit www.ararisbiotech.com or follow Araris on Twitter and LinkedIn. Corporate Contact: Dragan Grabulovski, Ph.D. Acting Chief Executive Officer …See details»
Araris Biotech - Company Profile - Tracxn
Oct 20, 2024 Araris Biotech ranks 41st among 2124 active competitors. 522 of its competitors are funded while 356 have exited. Overall, Araris Biotech and its competitors have raised over …See details»
Araris Biotech AG Announces Strategic Investment with Samsung …
For more information, please visit www.ararisbiotech.com or follow Araris on Twitter and LinkedIn. Corporate Contact: Philipp Spycher, Ph.D. Chief Executive Officer [email protected] …See details»
Araris Biotech AG to Present at 13th
Araris is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich. For more information, please visit www.ararisbiotech.com or follow Araris on Twitter and LinkedIn.See details»
Araris Biotech Completes CHF 15.2 Million Seed Financing Round
For more information, please visit www.ararisbiotech.com. Title: 201016_Press release Seed Araris_FINAL.pdf Created Date: 10/21/2020 7:31:54 PM ...See details»